NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free NEPH Stock Alerts $2.19 -0.08 (-3.52%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.19▼$2.3550-Day Range$2.11▼$3.7452-Week Range$1.05▼$4.04Volume3,277 shsAverage Volume20,102 shsMarket Capitalization$23.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Nephros alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Nephros Stock (NASDAQ:NEPH)Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More NEPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEPH Stock News HeadlinesMarch 11, 2024 | finanznachrichten.deNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 10, 2024 | finance.yahoo.comNephros Full Year 2023 Earnings: Misses ExpectationsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 9, 2024 | markets.businessinsider.comNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsMarch 9, 2024 | markets.businessinsider.comNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingMarch 8, 2024 | realmoney.thestreet.comNephros just upgraded at Benchmark, here's whyMarch 8, 2024 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comNEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 7, 2024 | globenewswire.comNephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 6, 2024 | benzinga.comEarnings Outlook For NephrosMarch 6, 2024 | markets.businessinsider.comNephros earnings: here's what to expectFebruary 29, 2024 | globenewswire.comNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsJanuary 28, 2024 | finance.yahoo.comWhat Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?January 24, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerJanuary 24, 2024 | finance.yahoo.comRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerDecember 18, 2023 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price BounceDecember 14, 2023 | morningstar.comNephros Inc NEPHDecember 13, 2023 | finance.yahoo.comAre Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?December 12, 2023 | msn.comNephros CEO buys 18k shares of the company - filingDecember 12, 2023 | msn.comTraeger heats up after attracting bull rating from B. RileyNovember 27, 2023 | msn.comNephros (NEPH) Price Target Increased by 50.00% to 4.59November 22, 2023 | markets.businessinsider.comBenchmark Co. Keeps Their Hold Rating on Nephros (NEPH)November 11, 2023 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | finance.yahoo.comBreakeven On The Horizon For Nephros, Inc. (NASDAQ:NEPH)November 8, 2023 | benzinga.comNephros: Q3 Earnings InsightsNovember 8, 2023 | finance.yahoo.comNephros Announces Results for Quarter Ended September 30, 2023See More Headlines Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-11.06% Pretax Margin-11.06% Return on Equity-18.25% Return on Assets-14.29% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio2.81 Sales & Book Value Annual Sales$14.24 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book2.74Miscellaneous Outstanding Shares10,544,000Free Float10,006,000Market Cap$23.09 million OptionableNot Optionable Beta1.34 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert BanksPresident, CEO & DirectorMs. Judy F. Krandel C.F.A. (Age 59)Chief Financial Officer Mr. Alfred VargasDirector of OperationsBrianne McGuireDirector of Brand, Marketing & Business DevelopmentVashone R. ThomasVice President of Quality, Regulatory, & Human ResourcesMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Executive Officer of Specialty Renal Products, Inc Comp: $300.18kMr. Greg LucasPresident of Aether Water SystemsMs. Judy MazziniControllerMore ExecutivesKey CompetitorsInspira Technologies Oxy B.H.N.NASDAQ:IINNMeihua International Medical TechnologiesNASDAQ:MHUAPetVivoNASDAQ:PETVAkiliNASDAQ:AKLIPAVmedNASDAQ:PAVMView All CompetitorsInsiders & InstitutionsWexford Capital LPSold 4,714 shares on 2/15/2024Ownership: 35.124%Robert R Jr. BanksBought 18,000 shares on 12/7/2023Total: $39,600.00 ($2.20/share)Robert R Jr. BanksBought 99 shares on 8/14/2023Total: $148.50 ($1.50/share)View All Insider TransactionsView All Institutional Transactions NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed in 2024? Nephros' stock was trading at $3.46 at the beginning of 2024. Since then, NEPH shares have decreased by 36.7% and is now trading at $2.19. View the best growth stocks for 2024 here. Are investors shorting Nephros? Nephros saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,800 shares, a decline of 64.7% from the February 29th total of 5,100 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company's shares are short sold. View Nephros' Short Interest. When is Nephros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NEPH earnings forecast. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $3.25 million for the quarter. Nephros had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 18.25%. Who are Nephros' major shareholders? Nephros' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wexford Capital LP (35.12%). Insiders that own company stock include Andrew Astor, Robert R Jr Banks, Tom Gwydir and Wesley S Lobo. View institutional ownership trends. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEPH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.